https://thepharmadata.com/ncardia-launches-ncyte-heart-in-a-release-1/ 2025-01-28T09:57:57+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Ncardia-Launches-Ncyte®-Heart-in-a-Box-for-Advancing-Precision-Cardiovascular-Research.webp https://thepharmadata.com/wp-content/uploads/2025/01/Ncardia.webp https://thepharmadata.com/enhertu-approved-in-u-s-for-endocrine-therapy/ 2025-01-28T10:14:20+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/ENHERTU®-Approved-in-U.S.-for-HER2-Low-Metastatic-Breast-Cancer-Post-Endocrine-Therapy.webp https://thepharmadata.com/wp-content/uploads/2025/01/Endocrine-1024x683.webp https://thepharmadata.com/cannabis-pharmaceuticals-market-2024-2034/ 2025-01-28T10:51:56+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Cannabis-Pharmaceuticals-Market-2024-2034-Focus-on-Sativex-Cesamet-Marinol-Epidiolex-ResearchAndMarkets.com_.webp https://thepharmadata.com/wp-content/uploads/2025/01/Pharmaceuticals-1024x683.webp https://thepharmadata.com/genentechs-itovebi-demonstrates-survival-benefit/ 2025-01-28T15:49:03+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Genentechs-Itovebi-Demonstrates-Survival-Benefit-in-HR-Positive-Advanced-Breast-Cancer.webp https://thepharmadata.com/wp-content/uploads/2025/01/Genentechs-Itovebi-Demonstrates-Survival-Benefit-in-HR-Positive-Advanced-Breast-Cancer-1.webp https://thepharmadata.com/inventia-life-science-launches-rastrum-allegro/ 2025-01-28T15:53:29+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Inventia-Life-Science-Launches-RASTRUM™-Allegro-to-Revolutionize-3D-Cell-Culture-in-Drug-Discovery.webp https://thepharmadata.com/wp-content/uploads/2025/01/Inventia-Life-Science-Launches-RASTRUM™-Allegro-to-Revolutionize-3D-Cell-Culture-in-Drug-Discovery-1.webp https://thepharmadata.com/sage-therapeutics-rejects-biogens-acquisition/ 2025-01-28T16:00:25+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Sage-Therapeutics-Rejects-Biogens-Acquisition-Proposal-Explores-Strategic-Alternatives.webp https://thepharmadata.com/wp-content/uploads/2025/01/Sage-Therapeutics-Rejects-Biogens-Acquisition-Proposal-Explores-Strategic-Alternatives-1.webp https://thepharmadata.com/trilobio-unveils-groundbreaking-whole-laboratory/ 2025-01-29T10:17:58+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Trilobio-Unveils-Groundbreaking-Whole-Laboratory-Automation-Platform-at-SLAS2025.webp https://thepharmadata.com/wp-content/uploads/2025/01/Trilobio-Unveils-Groundbreaking-Whole-Laboratory-Automation-Platform-at-SLAS2025-1-1024x538.webp https://thepharmadata.com/geminibio-appoints-matt-stober-to-board-of-direc/ 2025-01-29T10:22:08+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/GeminiBio-Appoints-Matt-Stober-to-Board-of-Directors.webp https://thepharmadata.com/wp-content/uploads/2025/01/GeminiBio-Appoints-Matt-Stober-to-Board-of-Directors-1-1024x513.webp https://thepharmadata.com/nanoemulsions-market-report-2024-2030-analysis/ 2025-01-29T11:35:10+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Nanoemulsions-Market-Report-2024-2030-Analysis-Forecasts-by-Drug-Class.webp https://thepharmadata.com/wp-content/uploads/2025/01/Nanoemulsions-Market-Report-2024-2030-Analysis-Forecasts-by-Drug-Class-1.webp https://thepharmadata.com/modella-ais-pathchat-co-pilot-earns-fda-break/ 2025-01-29T10:41:24+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Modella-AIs-PathChat-Co-Pilot-Earns-FDA-Breakthrough-Device-Status.webp https://thepharmadata.com/wp-content/uploads/2025/01/Modella-AIs-PathChat-Co-Pilot-Earns-FDA-Breakthrough-Device-Status-1-1024x683.webp https://thepharmadata.com/arizona-adhd-center-opens-new-scottsdale-clinic/ 2025-01-30T10:54:09+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Arizona-ADHD-Center-Opens-New-Scottsdale-Clinic-1.webp https://thepharmadata.com/dr-stephanie-simmons-of-photonic-inc-to-headli/ 2025-01-29T11:36:15+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Dr.-Stephanie-Simmons-to-Speak-at-UNESCOs-Quantum-Science-and-Technology-Kickoff.webp https://thepharmadata.com/wp-content/uploads/2025/01/Dr.-Stephanie-Simmons-of-Photonic-Inc.-to-Headline-UNESCOs-Quantum-Science-and-Technology-Launch-Event.webp https://thepharmadata.com/jcr-pharmaceuticals-to-showcase-at-the-21st/ 2025-01-29T11:22:39+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/JCR-Pharmaceuticals-to-Showcase-at-the-21st-Annual-WORLDSymposium™-2025.webp https://thepharmadata.com/wp-content/uploads/2025/01/JCR-Pharmaceuticals-to-Showcase-at-the-21st-Annual-WORLDSymposium™-2025-1.webp https://thepharmadata.com/scholar-rock-submits-bla-to-fda-for-apitegromab/ 2025-01-30T10:32:00+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Scholar-Rock-Submits-BLA-to-FDA-for-Apitegromab-in-SMA-Treatment.webp https://thepharmadata.com/wp-content/uploads/2025/01/Scholar-Rock-Submits-BLA-to-FDA-for-Apitegromab-in-SMA-Treatment-1-1024x536.webp https://thepharmadata.com/leveragen-moonlight-bio-partner-to-advance-t/ 2025-01-31T10:05:16+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Leveragen-Moonlight-Bio-Partner-to-Advance-T-Cell-Therapies-e1738298111595.jpg https://thepharmadata.com/wp-content/uploads/2025/01/Leveragen-Moonlight-Bio-Partner-to-Advance-T-Cell-Therapies.webp https://thepharmadata.com/immunitybio-beigene-launch-phase-3-trial-for/ 2025-01-30T10:43:00+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/ib-og-2024.webp https://thepharmadata.com/wp-content/uploads/2025/01/ImmunityBio-BeiGene-Launch-Phase-3-Trial-for-ANKTIVA®-and-PD-1-Inhibitor-in-NSCLC-1024x285.webp https://thepharmadata.com/new-poll-majority-of-americans-support-widesprea/ 2025-01-30T10:52:37+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/New-Poll-Majority-of-Americans-Support-Widespread-Vaccine-Access-for-Children-and-Communities.jpg https://thepharmadata.com/wp-content/uploads/2025/01/New-Poll-Majority-of-Americans-Support-Widespread-Vaccine-Access-for-Children-and-Communities.webp https://thepharmadata.com/tnf-pharmaceuticals-launches-study-series-to-pre/ 2025-01-30T10:59:19+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/TNF-Pharmaceuticals-Launches-Study-Series-to-Preserve-Lean-Muscle-Mass-During-GLP-1-Weight-Loss-Treatment.webp https://thepharmadata.com/wp-content/uploads/2025/01/TNF-Pharmaceuticals-Launches-Study-Series-to-Preserve-Lean-Muscle-Mass-During-GLP-1-Weight-Loss-Treatment-1.webp https://thepharmadata.com/global-pharmaceutical-rd-outsourcing-market-2025/ 2025-01-30T11:04:41+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Global-Pharmaceutical-RD-Outsourcing-Market-2025-Report-Now-Available-ResearchAndMarkets.com_.webp https://thepharmadata.com/wp-content/uploads/2025/01/Global-Pharmaceutical-RD-Outsourcing-Market-2025-Report-Now-Available-ResearchAndMarkets.com_-1.webp https://thepharmadata.com/biological-drugs-market-outlook-2024-projected/ 2025-01-30T11:10:12+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Biological-Drugs-Market-Outlook-2024-Projected-to-Reach-634.4-Billion-by-2030-Driven-by-Healthcare-Growth-and-Rising-Chronic-Diseases-ResearchAndMarkets.com_.webp https://thepharmadata.com/wp-content/uploads/2025/01/Biological-Drugs-Market-to-Hit-634.4-Billion-by-2030-Fueled-by-Healthcare-Expansion-and-Chronic-Disease-Surge.webp https://thepharmadata.com/new-data-shows-dct-components-enhance-clinical/ 2025-01-30T16:22:31+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/CORRECTING-and-REPLACING-New-Data-Shows-DCT-Components-Enhance-Clinical-Trial-Access-for-Underrepresented-Communities.webp https://thepharmadata.com/wp-content/uploads/2025/01/New-Data-Shows-DCT-Components-Enhance-Clinical-Trial-Access-for-Underrepresented-Communities-1024x683.webp https://thepharmadata.com/science-exchange-unveils-innovative-clinical/ 2025-01-31T10:03:18+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Science-Exchange-Unveils-Innovative-Clinical-Development-Solution-for-Enhanced-Research-Efficiency.webp https://thepharmadata.com/wp-content/uploads/2025/01/pexels-pixabay-356040-1024x682.webp https://thepharmadata.com/new-analysis-medicare-drug-price-negotiation/ 2025-01-31T10:23:41+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/New-Analysis-Medicare-Drug-Price-Negotiation-Program-Threatens-U.S.-Pharmacy-Stability.webp https://thepharmadata.com/wp-content/uploads/2025/01/pexels-polina-tankilevitch-3873191-1024x682.webp https://thepharmadata.com/biologics-market-2024-2030-global-growth-to/ 2025-01-31T10:34:49+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Biologics-Market-2024-2030-Global-Growth-to-732.4-Billion-Driven-by-Collaborations.webp https://thepharmadata.com/wp-content/uploads/2025/01/pexels-n-voitkevich-7172830-1024x682.webp https://thepharmadata.com/owkin-administers-first-dose-in-ai-optimized/ 2025-01-31T10:44:08+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Owkin-Administers-First-Dose-in-AI-Optimized-Phase-I-Trial-of-OKN4395-for-Solid-Tumors.webp https://thepharmadata.com/wp-content/uploads/2025/01/pexels-anntarazevich-8110794-1024x682.webp https://thepharmadata.com/lead-capital-partners-and-petra-capital-partners/ 2025-01-31T10:51:06+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Lead-Capital-Partners-and-Petra-Capital-Partners-Announce-Strategic-Platform-Investment-in-Lieberman.webp https://thepharmadata.com/wp-content/uploads/2025/01/cropped-site-identity-lead.webp https://thepharmadata.com/revbio-secures-key-patent-for-regenerative-bone/ 2025-01-31T11:01:24+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/RevBio-Secures-Key-Patent-for-Regenerative-Bone-Adhesive-Technology-in-the-US.webp https://thepharmadata.com/wp-content/uploads/2025/01/RevBio-Logo-SHARE_SMALLER-1024x511.webp https://thepharmadata.com/ferrer-earns-recognition-for-industry-leading/ 2025-01-31T11:11:04+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Ferrer-Earns-Recognition-for-Industry-Leading-Ethics-and-Compliance-Program.webp https://thepharmadata.com/wp-content/uploads/2025/01/Ferrer-Earns-Recognition-for-Industry-Leading-Ethics-and-Compliance-Program-2-1024x439.webp https://thepharmadata.com/enveric-biosciences-granted-patent-allowance-for/ 2025-01-31T11:25:58+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Enveric-Biosciences-Granted-Patent-Allowance-for-Lead-Drug-Candidate-EB-003-by-USPTO.webp https://thepharmadata.com/wp-content/uploads/2025/01/Enveric-Biosciences-Granted-Patent-Allowance-for-Lead-Drug-Candidate-EB-003-by-USPTO-2-1024x339.webp https://thepharmadata.com/koru-medical-systems-partners-on-phase-iii/ 2025-01-31T11:34:40+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/KORU-Medical-Systems-Partners-on-Phase-III-Clinical-Trial-for-Innovative-Nephrology-Drug-Indication.webp https://thepharmadata.com/wp-content/uploads/2025/01/KORU-Medical-Systems-Partners-on-Phase-III-Clinical-Trial-for-Innovative-Nephrology-Drug-Indication-2-1024x307.webp https://thepharmadata.com/quanta-system-celebrates-40years-and-partnership/ 2025-01-31T16:12:37+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Quanta-System_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Exclusive-Partnership_11zon.webp https://thepharmadata.com/galderma-pioneers-aesthetic-injectables-weight/ 2025-01-31T16:45:09+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Galderma-Leads-in-Aesthetic-Injectables_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Medication-Driven-Weight-Loss.jpg https://thepharmadata.com/owkin-doses-first-patient-for-solid-tumors/ 2025-01-31T17:15:51+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Owkin-Doses-First-Patient_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/01/Tranforming-Cancer-Treatment-with-AI-Driven-Drug-Development_11zon.webp https://thepharmadata.com/ethris-report-for-mrna-candidate-eth47-in-asthma/ 2025-01-31T17:46:03+05:30 https://thepharmadata.com/wp-content/uploads/2025/01/Ethris-Reports-Positive-Phase-1-Data.jpg https://thepharmadata.com/wp-content/uploads/2025/01/A-New-Era-for-RNA-Therapeutics-in-Respiratory-Diseases.jpg https://thepharmadata.com/imcas-2025-galderma-phase-iiib-data-show-rapid/ 2025-02-01T11:55:18+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/download.jpg https://thepharmadata.com/wp-content/uploads/2025/02/images-1_11zon.webp https://thepharmadata.com/sumitomo-pharma-reports-twymeeg-q4-2024-sales/ 2025-02-01T11:53:37+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Sumitomo-Pharma-Reports-TWYMEEG®-Q4-2024-Sales-and-Full-Year-Forecast-in-Japan.webp https://thepharmadata.com/wp-content/uploads/2025/02/Sumitomo-Pharma-Reports-TWYMEEG®-Q4-2024-Sales-and-Full-Year-Forecast-in-Japan-1-1024x538.webp https://thepharmadata.com/vertex-secures-casgevy-reimbursement-agreement/ 2025-02-01T11:57:45+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Vertex-Secures-CASGEVY®-Reimbursement-Agreement-for-Sickle-Cell-Disease-Treatment-in-England.webp https://thepharmadata.com/wp-content/uploads/2025/02/Vertex-Secures-CASGEVY®-Reimbursement-Agreement-for-Sickle-Cell-Disease-Treatment-in-England-2-1024x543.webp https://thepharmadata.com/median-technologies-eyonis-lcs-hits-primary/ 2025-02-03T13:10:52+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Median-Technologies.webp https://thepharmadata.com/inhalon-biopharma-unveils-first-inhaled-antibody/ 2025-02-03T14:19:36+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Inhalon-Biopharma-Unveils-First-Inhaled-Antibody-for-RSV-in-Human-Trials_11zon-1.webp https://thepharmadata.com/phase-3-trial-pfizers-braftovi-combo-boosts/ 2025-02-04T10:00:02+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Phase-3-Trial-Pfizers-BRAFTOVI®-Combo-Boosts-Survival.webp https://thepharmadata.com/cystic-fibrosis-biotech-sionna-announces-150m/ 2025-02-04T10:33:22+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Cystic-Fibrosis-Biotech-Sionna-Announces-Groundbreaking-150M-IPO-for-Treatment-Development_11zon.webp https://thepharmadata.com/bayer-heart-failure-seeks-eu-heart-failure/ 2025-02-04T10:49:45+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Bayer-Seeks-EU-Approval-for-Finerenone-in-Heart-Failure-2_11zon.webp https://thepharmadata.com/cosette-pharmaceuticals-names-brad-leonard-vp/ 2025-02-04T11:10:12+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Cosette-Pharmaceuticals-Names-Brad-Leonard-VP-of-Generics-Commercial-Operations_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Cosette-Pharmaceuticals_11zon-1-1024x682.webp https://thepharmadata.com/advancell-closes-oversubscribed-112m-series/ 2025-02-04T11:32:39+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/AdvanCell-Closes-Oversubscribed-112M-Series-C-Funding_11zon.webp https://thepharmadata.com/dd-pharmatech-completes-48-week-phase-2-trial/ 2025-02-04T11:45:19+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/DD-Pharmatech-Completes-Enrollment-for-48-Week-Phase-2-Trial-of-DD01-in-MASH_11zon.webp https://thepharmadata.com/nucleic-acid-solutions-trilink-biotechnologie/ 2025-02-04T12:11:57+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Nucleic-Acid-Solutions-TriLink-BioTechnologies®-and-Avantor®-Partner-to-Expand-Access-in-Europe.webp https://thepharmadata.com/wp-content/uploads/2025/02/Nucleic-Acid-Solutions-TriLink-BioTechnologies®-and-Avantor®-Partner-to-Expand-Access-in-Europe-2-1024x678.webp https://thepharmadata.com/dnanexus-strengthens-veeva-partnership-for-globa/ 2025-02-04T12:32:01+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/DNAnexus-Strengthens-Veeva-Partnership-for-Global-Regulatory-Collaboration_11zon.webp https://thepharmadata.com/nsclc-nuvation-bio-launches-u-s-expexpanded/ 2025-02-04T13:00:57+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Nuvation-Bio-Launches-U.S.-Expanded-Access-Program-for-Taletrectinib-in-ROS1-NSCLC_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/NSCLC-Patients-Nuvation-Bio-Launches-U.S.-Expanded-Access-Program-for-Taletrectinib-in-ROS1_11zon-1024x682.webp https://thepharmadata.com/algiax-reports-positive-phase-2a-result-ap-325/ 2025-02-04T13:49:24+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Algiax-Reports-Positive-Phase-2a-Results-for-AP-325-in-Neuropathic-Pain-2_11zon.webp https://thepharmadata.com/patient-centric-medidata-pioneer-innovations/ 2025-02-04T14:16:30+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Medidata-Pioneers-AI-Driven-Patient-Centric-Innovations_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Patient-Centric-Medidata_11zon-1024x682.webp https://thepharmadata.com/enveric-biosciences-completes-5-million-public/ 2025-02-04T14:31:23+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Enveric-Biosciences-Completes-5-Million-Public-Offering_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Enveric-Biosciences-Completes-5-Million-Public-Offering-2_11zon-1024x682.webp https://thepharmadata.com/cagent-vascular-unveils-new-serranator/ 2025-02-04T14:48:58+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Cagent-Vascular-Unveils-New-Serranator-SL-PRO-Product-for-CLTI-and-Pedal-Disease_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Cagent-Vascular-Unveils-New-Serranator-SL-PRO-Product-for-CLTI-and-Pedal-Disease-2_11zon-1024x683.webp https://thepharmadata.com/disease-control-pioneer-dr-daniel-l-shungu/ 2025-02-05T09:46:58+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Marquis-Whos-Who-Recognizes-Dr.-Daniel-L.-Shungu-for-Leadership-in-Disease-Control_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Disease-Control-Pioneer-Dr.-Daniel-L.-Shungu-Recognized-by-Marquis-Whos-Who-for-Leadership-1024x682.webp https://thepharmadata.com/tonix-pharmaceuticals-appoints-siobhan-fogarty/ 2025-02-05T10:10:58+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Tonix-Pharmaceuticals-Appoints-Siobhan-Fogarty-as-Chief-Technical-Officer_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Tonix-Pharmaceuticals-Appoints-Siobhan-Fogarty-as-Chief-Technical-Officer-2_11zon-1024x682.webp https://thepharmadata.com/pepto-bismol-beyond-pink-5-symptom-relief-you/ 2025-02-05T10:45:52+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Pepto-Bismol-Beyond-Pink-–-5-Symptom-Relief-You-Can-Trust.webp https://thepharmadata.com/survey-88-of-western-europeans-seek-better/ 2025-02-05T10:57:17+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Survey-88-of-Western-Europeans-Seek-Better-Breast-Cancer-Info_11zon.webp https://thepharmadata.com/oa-pain-zoetis-updates-u-s-label-for-librela/ 2025-02-05T11:06:53+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Zoetis-Updates-U.S.-Label-for-Librela®-to-Treat-Canine-OA-Pain.webp https://thepharmadata.com/fibromyalgia-treatment-highmark-now-covers-fda/ 2025-02-05T11:14:21+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Highmark-Now-Covers-FDA-Cleared-Fibromyalgia-Treatment-by-Swing-Therapeutics_11zon.webp https://thepharmadata.com/os-therapies-shares-latest-corporate-develop/ 2025-02-05T11:32:43+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/OS-Therapies-Shares-Latest-Corporate-Developments_11zon.webp https://thepharmadata.com/inhaled-treprostinil-united-therapeutics/ 2025-02-05T11:44:47+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/United-Therapeutics-Completes-TETON-1-Enrollment-for-Inhaled-Treprostinil-in-IPF_11zon.webp https://thepharmadata.com/anti-inflammatory-devonian-health-group-reports/ 2025-02-05T12:27:07+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Devonian-Health-Group-Reports-Superior-Anti-Inflammatory-Potency-of-Thykamine™.webp https://thepharmadata.com/leo-pharma-reports-positive-delta-teen-results/ 2025-02-05T12:37:47+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/LEO-Pharma-Reports-Positive-DELTA-TEEN-Results-for-Anzupgo®-in-Adolescent-CHE.webp https://thepharmadata.com/wp-content/uploads/2025/02/LEO-Pharma-Reports-Positive-DELTA-TEEN-Results-for-Anzupgo®-in-Adolescent-CHE-2-1024x682.webp https://thepharmadata.com/joint-disease-enveric-biosciences-restoration/ 2025-02-05T12:49:33+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Enveric-Biosciences-Restoration-Biologics-Sign-Licensing-Deals-for-Joint-Disease-Treatment_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Joint-Disease-Enveric-Biosciences-Restoration-Biologics-Sign-Licensing-Deals-for-Treatment_11zon-1024x633.webp https://thepharmadata.com/pharmacy-solutions-walgreens-celebrates-one/ 2025-02-05T13:05:50+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Walgreens-Celebrates-One-Year-of-Deans-Advisory-Council-Advancing-Pharmacy-Solutions_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Pharmacy-Solutions-Walgreens-Celebrates-One-Year-of-Deans-Advisory-Council-Advancement_11zon-1024x575.webp https://thepharmadata.com/pharmaceutics-jabil-completes-acquisition/ 2025-02-05T14:09:47+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Jabil-Completes-Acquisition-of-Pharmaceutics-International_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Pharmaceutics-Jabil-Completes-Acquisition-of-Pharmaceutics-International_11zon.webp https://thepharmadata.com/cardio-diagnostics-partners-with-7-providers/ 2025-02-06T11:53:41+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Cardio-Diagnostics-Partners-with-7-Providers-to-Expand-AI-Driven-Cardiovascular-Tests_11zon.webp https://thepharmadata.com/vaccines-and-therapeutics-africa-europe-partner/ 2025-02-06T15:08:30+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Vaccines-and-Therapeutics-Africa-Europe-Partner-to-Advance-RNA-Based-Solutions_11zon-1-1.webp https://thepharmadata.com/wp-content/uploads/2025/02/Vaccines-and-Therapeutics-Africa-Europe-Partner-to-Advance-RNA-Based-Solutions-1024x682.webp https://thepharmadata.com/turn-therapeutics-achieves-24-hour-stability/ 2025-02-06T15:32:07+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Turn-Therapeutics-Achieves-24-Hour-Stability-for-Intranasal-Live-Vaccine-at-Room-Temperature_11zon.webp https://thepharmadata.com/medications-from-miist-therapeutics-secures-7m/ 2025-02-06T15:47:42+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Miist-Therapeutics-Secures-7M-in-Funding-to-Develop-Rapid-Acting-Medications_11zon.webp https://thepharmadata.com/new-breast-imaging-legislation-set-to-benefit/ 2025-02-06T16:06:07+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/New-Breast-Imaging-Legislation-Set-to-Benefit-Thousands-Across-Pennsylvania_11zon.webp https://thepharmadata.com/cencora-announces-first-quarter-results-2025/ 2025-02-06T16:18:39+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Cencora-Announces-First-Quarter-Results-for-Fiscal-2025_11zon.webp https://thepharmadata.com/phase-1-data-prolong-pharmaceuticals-to-present/ 2025-02-06T16:36:56+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Prolong-Pharmaceuticals-to-Present-Preliminary-Phase-1-Data-for-PP-007-in-AIS-at-2025-ISC_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Phase-1-Data-Prolong-Pharmaceuticals-to-Present-Preliminary-PP-007-Findings-for-AIS-at-2025-ISC_11zon-1024x682.webp https://thepharmadata.com/marquis-whos-who-honors-cheryl-custard-for-rd/ 2025-02-07T10:33:17+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Marquis-Whos-Who-Honors-Cheryl-Custard-for-RD-Expertise_11zon.webp https://thepharmadata.com/clinical-research-leader-claxton-copeland/ 2025-02-07T10:48:20+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Claxton-Copeland-III-Honored-for-Clinical-Research-Expertise-by-Marquis-Whos-Who_11zon.webp https://thepharmadata.com/clinical-applications-expert-hong-jiang/ 2025-02-07T11:01:26+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Hong-Jiang-MD-PhD-Excels-in-Translating-Scientific-Discoveries-into-Clinical-Applications.webp https://thepharmadata.com/pharmascience-signet-athyrium-hildred-exit/ 2025-02-07T11:42:37+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Signet-Athyrium-Hildred-and-Pharmascience-Exit-Pharmaceutics-International_11zon.webp https://thepharmadata.com/onc-ai-secures-fda-breakthrough-device-design/ 2025-02-07T12:18:03+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Onc.AI-Secures-FDA-Breakthrough-Device-Designation-for-AI-Powered-CT-Response-Model_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Onc.AI-Secures-FDA-Breakthrough-Device-Designation-for-AI-Powered-CT-Response-Model-2_11zon-1024x682.webp https://thepharmadata.com/goodrx-names-christopher-a-mcginnis-as-cfo/ 2025-02-07T14:25:22+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/GoodRx-Names-Christopher-A.-McGinnis-as-CFO_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/GoodRx-Names-Christopher-A.-McGinnis-as-CFO-2_11zon-1024x682.webp https://thepharmadata.com/know-labs-technology-licensing-ktl-announces/ 2025-09-30T13:01:50+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Know-Labs-Technology-Licensing-KTL-Announces-Official-Client-Partnership_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Know-Labs-Technology-Licensing-KTL-Announces-Official-Client-Partnership-2_11zon-1024x682.webp https://thepharmadata.com/dlbcl-treatment-merck-begins-phase-3-trial/ 2025-02-07T15:22:49+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Merck-Begins-Phase-3-Trial-of-Zilovertamab-Vedotin-for-DLBCL-Treatment_11zon.webp https://thepharmadata.com/broken-string-biosciences-unveils-catalyst/ 2025-02-07T15:51:09+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Broken-String-Biosciences-Unveils-Catalyst-Program-to-Accelerate-Gene-Editing-Therapy-Development_11zon.webp https://thepharmadata.com/antibodies-com-cactus-partner-to-speed-up/ 2025-02-07T16:43:07+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Antibodies.com-Cactus-Partner-to-Speed-Up-Life-Science-Publishing_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Antibodies.com-Cactus-Partner-to-Speed-Up-Life-Science-Publishing-2_11zon-1024x682.webp https://thepharmadata.com/fabry-disease-sangamo-reports-updated-phase-1-2/ 2025-02-07T17:13:30+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Sangamo-Reports-Updated-Phase-12-STAAR-Data-for-Fabry-Disease_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Fabry-Disease-Sangamo-Reports-Updated-Phase-12-STAAR-Data-for-Fabry-Disease_11zon-1024x682.webp https://thepharmadata.com/breast-cancer-treatment-therasyn-bio-rubix/ 2025-02-08T10:36:17+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Breast-Cancer-Treatment-TheraSyn-Bio-Rubix-LS-Launch-Project-Panacea-Revolutionary-Breast-Cancer-Treatment_11zon-1.webp https://thepharmadata.com/wp-content/uploads/2025/02/TheraSyn-Bio-Rubix-LS-Launch-Project-Panacea-Revolutionary-Breast-Cancer-Treatment_11zon-1024x682.webp https://thepharmadata.com/protein-prediction-lg-develops-ai-powered/ 2025-02-08T11:40:29+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/LG-Develops-AI-Powered-Protein-Prediction-for-Drug-Discovery_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Protein-Prediction-LG-Develops-AI-Powered-Protein-Prediction-for-Drug-Discovery_11zon-1024x682.webp https://thepharmadata.com/regeneron-regn-shareholders-urged-to-join/ 2025-02-08T12:07:45+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Regeneron-REGN-Shareholders-Urged-to-Join-Class-Action-–-Contact-Levi-Korsinsky-for-Details.webp https://thepharmadata.com/wp-content/uploads/2025/02/Regeneron-REGN-Shareholders-Urged-to-Join-Class-Action-–-Contact-Levi-Korsinsky-for-Details-3-1024x682.webp https://thepharmadata.com/kidney-transplant-eledon-pharma-highlights/ 2025-02-08T12:43:14+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Eledon-Pharma-Highlights-Tegoprubart-in-Second-Pig-Kidney-Transplant-to-Human_11zon-2_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Kidney-Transplant-Eledon-Pharma-Highlights-Tegoprubart-in-Second-Pig-Kidney-Transplant-to-Human_11zon-1024x682.webp https://thepharmadata.com/nutriband-secures-u-s-patent-approval-for-aversa/ 2025-02-08T13:00:53+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Nutriband-Secures-U.S.-Patent-Approval-for-Aversa™-Transdermal-Abuse-Deterrent-Technology-e1739162536509.webp https://thepharmadata.com/wp-content/uploads/2025/02/Nutriband-Secures-U.S.-Patent-Approval-for-Aversa™-Transdermal-Abuse-Deterrent-Technology-2-1024x682.webp https://thepharmadata.com/bristol-myers-squibb-reports-positive/ 2025-02-11T09:49:22+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Bristol-Myers-Squibb-Reports-Positive-Breyanzi®-Results-in-Relapsed-Marginal-Zone-Lymphoma.webp https://thepharmadata.com/wp-content/uploads/2025/02/Bristol-Myers-Squibb_11zon.webp https://thepharmadata.com/kalvista-presents-new-sebetralstat-wsaai-2025/ 2025-02-11T11:09:59+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/KalVista-Presents-New-Sebetralstat-Data-at-WSAAI-2025-1.webp https://thepharmadata.com/wp-content/uploads/2025/02/KalVista-Presents-1024x682.webp https://thepharmadata.com/aurion-biotech-names-donald-munoz-as-chief/ 2025-02-11T10:56:58+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Aurion-Biotech-Names-Donald-Munoz-as-Chief-Financial-Officer-1.webp https://thepharmadata.com/wp-content/uploads/2025/02/Aurion-Biotech-Names-Donald-Munoz-as-Chief-Financial-Officer-1024x682.webp https://thepharmadata.com/wp-content/uploads/2025/02/Chief-Financial-Officer-1024x682.webp https://thepharmadata.com/incyte-announces-q4-and-full-year-2024/ 2025-02-11T10:23:30+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Incyte-Announces-Q4-and-Full-Year-2024-Financial-Results-Shares-2025-Guidance-and-RD-Milestones.webp https://thepharmadata.com/wp-content/uploads/2025/02/Incyte-Announces-Q4-and-Full-Year-2024-1024x682.webp https://thepharmadata.com/arrowhead-sarepta-finalize-global-licensing/ 2025-02-11T16:00:33+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Arrowhead-Pharmaceuticals-Completes-Global-License-and-Collaboration-Deal-with-Sarepta-Therapeutics.webp https://thepharmadata.com/wp-content/uploads/2025/02/Arrowhead-Pharmaceuticals_11zon.webp https://thepharmadata.com/gensight-biologics-reports-five-year/ 2025-02-13T09:57:57+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/GenSight-Biologics-Reports-Five-Year-Efficacy-and-Safety-Results-of-LUMEVOQ®-Gene-Therapy-from-the-REFLECT-Study.webp https://thepharmadata.com/wp-content/uploads/2025/02/GenSight-Biologics-Reports-Five-Year-Efficacy-and-Safety-Results-of-LUMEVOQ-1024x682.webp https://thepharmadata.com/taiho-oncology-europe-announces-availability/ 2025-02-13T10:07:12+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Taiho-Oncology-Europe-Announces-Availability-of-Futibatinib-in-Italy.webp https://thepharmadata.com/wp-content/uploads/2025/02/Taiho-Oncology-Europe-Announces-Availability-of-Futibatinib-in-Italy-for-the-Treatment-of-Cholangiocarcinoma-1-1024x537.webp https://thepharmadata.com/seaport-therapeutics-reports-55-lymphatic/ 2025-02-13T10:16:33+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Seaport-Therapeutics-Publishes-Research-on-Glyph™-Platforms-55-Lymphatic-Drug-Absorption.webp https://thepharmadata.com/wp-content/uploads/2025/02/Seaport-Therapeutics.webp https://thepharmadata.com/abcuro-raises-200m-in-series-c-for-inclusion/ 2025-02-13T10:24:14+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Abcuro-Secures-200M-Series-C-to-Advance-Inclusion-Body-Myositis-Drug-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/Abcuro-Secures-200M-Series-C-to-Advance-Inclusion-Body-Myositis-Drug-1024x682.webp https://thepharmadata.com/alto-neuroscience-reports-positive-interim-resu/ 2025-02-13T10:35:06+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Alto-Neuroscience-Reports-Positive-Interim-Results-from-ALTO-300-Phase-2b-MDD-Trial.webp https://thepharmadata.com/wp-content/uploads/2025/02/Alto-Neuroscience-Reports-Positive-Interim-Results-from-ALTO-300-Phase-2b-MDD-Trial_11zon-1024x331.webp https://thepharmadata.com/real-world-outcomes-data-for-adstiladrin/ 2025-02-13T11:35:43+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Real-World-Outcomes-Data-for-ADSTILADRIN®-to-Be-Presented-at-2025-ASCO-Genitourinary-Symposium-1-1.webp https://thepharmadata.com/wp-content/uploads/2025/02/Real-World-Outcomes-Data-for-ADSTILADRIN®-to-Be-Presented-at-2025-ASCO-Genitourinary-Symposium.webp https://thepharmadata.com/tivic-health-acquires-global-rights-to-phase/ 2025-02-13T11:43:27+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Tivic-Health-Secures-Global-Rights-to-Phase-III.webp https://thepharmadata.com/wp-content/uploads/2025/02/Tivic-Health-Secures-Global-Rights-to-Phase-III-TLR5-Agonist-from-Statera-Biopharma_11zon.webp https://thepharmadata.com/altpep-corporation-a-privately-held/ 2025-02-13T11:52:41+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/AltPep-Corporation-Welcomes-Dr.-Alan-Colowick-to-Board-of-Directors.webp https://thepharmadata.com/wp-content/uploads/2025/02/AltPep-Corporation-Welcomes-Dr.-Alan-Colowick-to-Board-of-Directors_11zon.webp https://thepharmadata.com/opna-bios-opn-6602-gains-orphan-drug/ 2025-02-13T12:00:50+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Opna-Bios-OPN-6602-Gains-Orphan-Drug-Status-for-Multiple-Myeloma.webp https://thepharmadata.com/wp-content/uploads/2025/02/Opna-Bios-OPN-6602-Gains-Orphan-Drug-Status-for-Multiple-Myeloma_11zon.webp https://thepharmadata.com/latent-labs-secures-50m-for-ai-powered-biology/ 2025-02-14T11:03:40+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Latent-Labs-Raises-50M-to-Advance-AI-Driven-Programmable-Biology.webp https://thepharmadata.com/wp-content/uploads/2025/02/Latent-Labs-Secures-50M-in-Funding-to-Realize-the-Potential-of-AI-Powered-Programmable-Biology.webp https://thepharmadata.com/ensomas-en-374-gains-rare-orphan-drug-status/ 2025-02-14T11:24:44+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Ensoma-Secures-Rare-Pediatric-Disease-Orphan-Drug-Status-for-EN-374-in-Chronic-Granulomatous-Disease.webp https://thepharmadata.com/wp-content/uploads/2025/02/Ensoma-Secures-Rare-Pediatric-Disease-Orphan-Drug-Status-for-EN-374-in-Chronic-Granulomatous-Disease_11zon.webp https://thepharmadata.com/newleos-launches-93-5m-for-neuropsychiatric/ 2025-02-14T11:33:39+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Newleos-Launches-with-93.5M-to-Advance-Neuropsychiatric-Treatments.webp https://thepharmadata.com/wp-content/uploads/2025/02/Newleos-Launches-with-93.5M-to-Advance-Neuropsychiatric-Treatments_11zon.webp https://thepharmadata.com/renovorx-showcases-promising-preclinical-data/ 2025-02-14T11:39:35+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/RenovoRx-Showcases-Promising-Preclinical-Data-on-TAMP™-Drug-Delivery-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/RenovoRx-Showcases-Promising-Preclinical-Data-on-TAMP™-Drug-Delivery.webp https://thepharmadata.com/quantum-si-showcases-next-gen-protein-sequencing/ 2025-02-14T11:46:21+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Quantum-Si-and-Researchers-to-Present-Next-Gen-Protein.webp https://thepharmadata.com/wp-content/uploads/2025/02/Quantum-Si-and-Researchers-to-Present-Next-Gen-Protein-Sequencing™-at-US-HUPO-2025.webp https://thepharmadata.com/junevity-10m-advance-cell-reset-therapies/ 2025-02-14T11:53:50+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Junevity-Secures-10M-to-Advance-Cell-Reset-Therapies-for-Longevity-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/Junevity-Secures-10M-to-Advance-Cell-Reset-Therapies-for-Longevity.webp https://thepharmadata.com/tempus-partners-with-ifli-to-advance-development/ 2025-02-14T11:59:52+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Tempus-Partners-with-IFLI-to-Advance-Development-of.webp https://thepharmadata.com/wp-content/uploads/2025/02/Tempus-Partners-with-IFLI-to-Advance-Development-of-Targeted-Therapies-for-Follicular-Lymphoma_11zon.webp https://thepharmadata.com/genedx-launches-ultrarapid-whole-genome/ 2025-02-14T12:06:32+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/GeneDx-Launches-ultraRapid-Whole-Genome.webp https://thepharmadata.com/wp-content/uploads/2025/02/GeneDx-Launches-ultraRapid-Whole-Genome-Sequencing-for-NICU-and-PICU-Patients_11zon.webp https://thepharmadata.com/eu-approves-nemluvio-for-atopic-dermatitis/ 2025-02-15T10:00:48+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/EU-Approves-Nemluvio®-for-Atopic-Dermatitis-Prurigo-Nodularis-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/EU-Approves-Nemluvio®-for-Atopic-Dermatitis-Prurigo-Nodularis.webp https://thepharmadata.com/os-therapies-initiates-commercial-manufacturing/ 2025-02-15T10:14:48+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/OS-Therapies-Initiates-Commercial-Manufacturing-of-OST-HER2-Ahead-of-Biologics-License-Application-BLA-Submission.webp https://thepharmadata.com/wp-content/uploads/2025/02/OS-Therapies-Initiates-Commercial-Manufacturing-of-OST-HER2-Ahead-of-Biologics-License-Application-BLA-Submission_11zon.webp https://thepharmadata.com/european-commission-approves-kostaive-the/ 2025-02-15T10:28:02+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/European-Commission-Approves-KOSTAIVE®-the-First-Self-Amplifying-mRNA-COVID-19.webp https://thepharmadata.com/wp-content/uploads/2025/02/European-Commission-Approves-KOSTAIVE®-1024x682.webp https://thepharmadata.com/anebulo-pharmaceuticals-announces-q2-fy-2025/ 2025-02-15T11:29:01+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Anebulo-Pharmaceuticals-Announces-Q2-FY-2025-Financial-Results-and-Key-Updates.webp https://thepharmadata.com/wp-content/uploads/2025/02/Anebulo-Pharmaceuticals-Announces-Q2-FY-2025-Financial-Results-and-Key-Updates_11zon.webp https://thepharmadata.com/u-s-fda-fully-approves-decipheras-romvimza/ 2025-02-15T11:44:17+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/U.S.-FDA-Fully-Approves-Decipheras-ROMVIMZA™-for-TGCT-Treatment-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/U.S.-FDA-Fully-Approves-Decipheras-ROMVIMZA™-for-TGCT.webp https://thepharmadata.com/wp-content/uploads/2025/02/U.S.-FDA-Fully-Approves-Decipheras-ROMVIMZA™-for-TGCT-Treatment.webp https://thepharmadata.com/wp-content/uploads/2025/02/U.S.-FDA-Fully-Approves-Decipheras-ROMVIMZA-1024x682.webp https://thepharmadata.com/fda-grants-breakthrough-status-to-innate/ 2025-02-18T09:50:02+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/FDA-Grants-Breakthrough-Status-to-Innate-Pharmas-Lacutamab-for-Sezary-Syndrome-2-scaled.webp https://thepharmadata.com/wp-content/uploads/2025/02/FDA-Grants-Breakthrough-Status-to-Innate-Pharmas-Lacutamab-for-Sezary-Syndrome.webp https://thepharmadata.com/edx-medical-in-the-uk-develops-advanced-super/ 2025-02-18T10:03:40+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/EDX-Medical-in-the-UK-Develops-Advanced-‘Super-Test-for-Prostate-Cancer.webp https://thepharmadata.com/wp-content/uploads/2025/02/EDX-Medical-in-the-UK-Develops-Advanced-‘Super-Test-for-Prostate-Cancer-1.webp https://thepharmadata.com/limmatech-starts-phase-1-trial-for-s-aureus/ 2025-02-18T10:14:05+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/LimmaTech-Starts-Phase-1-Trial-for-S.-aureus-Vaccine-scaled.webp https://thepharmadata.com/wp-content/uploads/2025/02/LimmaTech-Starts-Phase-1-Trial-for-S.-aureus-Vaccine-LBT-SA7_11zon.webp https://thepharmadata.com/fda-approves-gsks-penmenvy-a-5-in-1/ 2025-02-18T10:21:03+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/FDA-Approves-GSKs-PENMENVY-a-5-in-1-Meningococcal.webp https://thepharmadata.com/wp-content/uploads/2025/02/FDA-Approves-GSKs-PENMENVY-a-5-in-1-Meningococcal-Vaccine-for-MenABCWY-Protection-1024x317.webp https://thepharmadata.com/innocare-gets-approval-for-phase-iii-study-of/ 2025-02-18T10:27:33+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/InnoCare-Gets-Approval-for-Phase-III-Study-of-ICP-248-and-Orelabrutinib.webp https://thepharmadata.com/wp-content/uploads/2025/02/InnoCare-Gets-Approval-for-Phase-III-Study-of-ICP-248-and-Orelabrutinib-for-First-Line-CLLSLL-Therapy-in-China-1024x684.webp https://thepharmadata.com/pneuma-respiratory-pioneers-inhaled-therapies/ 2025-02-18T10:33:56+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Pneuma-Respiratory-Pioneers-Inhaled-Therapies-to-Enhance-Respiratory-Health.webp https://thepharmadata.com/wp-content/uploads/2025/02/Pneuma-Respiratory-Pioneers-Inhaled-Therapies-to-Enhance-Respiratory-Health_11zon-1024x537.webp https://thepharmadata.com/icc-arbitral-tribunal-decides-in-favor-of-aop/ 2025-02-18T10:41:00+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/ICC-Arbitral-Tribunal-Decides-in-Favor-of-AOP-Health-in-Arbitration.webp https://thepharmadata.com/wp-content/uploads/2025/02/ICC-Arbitral-Tribunal-Decides-in-Favor-of-AOP-Health-in-Arbitration-over-BESREMi®-Ropeginterferon-alfa-2b.webp https://thepharmadata.com/galdermas-nemluvio-approved-in-uk-switzerlan/ 2025-02-19T10:29:00+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Galdermas-Nemluvio®-Approved-in-UK-Switzerland-for-Skin-Conditions-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/Galdermas-Nemluvio®-Approved-in-UK-Switzerland-for-Skin-Conditions.webp https://thepharmadata.com/genedx-announces-q4-and-full-year-2024/ 2025-02-19T10:36:25+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/GeneDx-Announces-Q4-and-Full-Year-2024-Financial-Results.webp https://thepharmadata.com/wp-content/uploads/2025/02/GeneDx-Announces-Q4-and-Full-Year-2024-Financial-Results-and-Provides-2025-Guidance_11zon.webp https://thepharmadata.com/pharmajet-to-showcase-advantages-of-needle/ 2025-02-20T09:46:40+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/PharmaJet-to-Showcase-Advantages-of-Needle-Free.webp https://thepharmadata.com/wp-content/uploads/2025/02/PharmaJet-to-Showcase-Advantages-of-Needle-Free-Intradermal-Delivery-at-Medical-Conference-in-Ethiopia-1024x573.webp https://thepharmadata.com/reverb-therapeutics-raises-12m-to-advance/ 2025-02-20T09:56:10+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Reverb-Therapeutics-Raises-12M-to-Advance-Amplify•R™-Platform-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/Reverb-Therapeutics-Raises-12M-to-Advance-Amplify•R™-Platform.webp https://thepharmadata.com/precision-biosciences-reports-initial-safety-and/ 2025-02-20T10:03:22+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Precision-BioSciences-Reports-Initial-Safety-and-Antiviral-Activity-Data-for-PBGENE-HBV-in-the-ELIMINATE-B-Trial.webp https://thepharmadata.com/wp-content/uploads/2025/02/Precision-BioSciences-Reports-Initial-Safety-and-Antiviral-Activity-1024x356.webp https://thepharmadata.com/wp-content/uploads/2025/02/Precision-BioSciences-Reports-Initial-Safety-and-Antiviral_11zon.webp https://thepharmadata.com/stablepharma-awarded-e2-5m-eic-accelerator-grant/ 2025-02-20T10:08:14+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Stablepharma-Awarded-E2.5M-EIC-Accelerator-scaled.webp https://thepharmadata.com/wp-content/uploads/2025/02/Stablepharma-Awarded-E2.5M-EIC-Accelerator-Grant-Named-Among-Europes-Top-71-Innovators.webp https://thepharmadata.com/celerion-expands-uk-phase-1-trials-at-queen/ 2025-02-20T10:14:13+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Celerion-Expands-UK-Phase-1-Trials-at-Queens.webp https://thepharmadata.com/wp-content/uploads/2025/02/Celerion-Expands-UK-Phase-1-Trials-at-Queens-University-Belfasts-iREACH-Health.webp https://thepharmadata.com/alzamend-neuro-completes-tesla-head-coil-for/ 2025-02-20T10:20:09+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Alzamend-Neuro-Completes-Tesla.webp https://thepharmadata.com/wp-content/uploads/2025/02/Alzamend-Neuro-Completes-Tesla-Head-Coil-for-Phase-II-Trials-at-MGH_11zon.webp https://thepharmadata.com/ventus-therapeutics-names-dr-mona-kotecha/ 2025-02-20T10:25:44+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Ventus-Therapeutics-Names-Dr.-Mona-Kotecha-as-Chief-Medical-Officer.webp https://thepharmadata.com/wp-content/uploads/2025/02/Ventus-Therapeutics-Names-Dr.-Mona-Kotecha-as-Chief-Medical-Officer_11zon.webp https://thepharmadata.com/lantern-pharma-publishes-pct-patent-for-ai/ 2025-02-20T10:31:25+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Lantern-Pharma-Publishes-PCT-Patent-for-AI-Model-Predicting-BBB-Permeability.webp https://thepharmadata.com/wp-content/uploads/2025/02/Lantern-Pharma-Publishes-PCT-Patent-for-AI-Model-Predicting-BBB-Permeability_11zon.webp https://thepharmadata.com/eikon-therapeutics-showcases-oblique-line/ 2025-09-30T13:01:41+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Eikon-Therapeutics-Showcases-Oblique-Line-Scan-Tech-in-Nature-Method.webp https://thepharmadata.com/wp-content/uploads/2025/02/Eikon-Therapeutics-Showcases-Oblique-Line-Scan-Tech-in-Nature-Method_11zon.webp https://thepharmadata.com/released-for-treating-candida-fungal-infections/ 2025-02-22T09:55:20+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/New-International-Guidelines-Released-for-Treating-Candida-Fungal-Infections.webp https://thepharmadata.com/wp-content/uploads/2025/02/New-International-Guidelines-Released-for-Treating-Candida-Fungal-Infections-2-1024x684.webp https://thepharmadata.com/sensorion-gets-positive-board-recommendation/ 2025-02-22T10:03:58+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Sensorion-Gets-Positive-Board-Recommendation-for-SENS-501-Trial.webp https://thepharmadata.com/wp-content/uploads/2025/02/Sensorion-Gets-Positive-Board-Recommendation-for-SENS-501-Trial_11zon-1024x538.webp https://thepharmadata.com/recerise-advances-collaboration-for-hepatocellu/ 2025-02-22T10:23:50+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/ReCerise-Advances-Collaboration-for-Hepatocellular-Carcinoma-Treatment.webp https://thepharmadata.com/wp-content/uploads/2025/02/ReCerise-Advances-Collaboration-for-Hepatocellular-1024x537.webp https://thepharmadata.com/go-reply-sprint-reply-use-ai-to-automate/ 2025-02-22T10:25:12+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Go-Reply-Sprint-Reply-Use-AI-to-Automate-Clinical-Study.webp https://thepharmadata.com/wp-content/uploads/2025/02/Go-Reply-Sprint-Reply-Use-AI-to-Automate-Clinical-Study-Reports-for_11zon.webp https://thepharmadata.com/kalvista-to-present-new-sebetralstat-data-aaaai/ 2025-02-22T11:46:01+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/KalVista-to-Present-New-Sebetralstat-Data-at-AAAAI-2025-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/KalVista-to-Present-New-Sebetralstat-Data-at-AAAAI-2025_11zon.webp https://thepharmadata.com/seaport-therapeutics-analyzes-trial-design/ 2025-02-22T10:40:49+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Seaport-Therapeutics-Analyzes-Trial-Design-and.webp https://thepharmadata.com/wp-content/uploads/2025/02/Seaport-Therapeutics-Analyzes-Trial-Design-and-Placebo-Response-in-MDD_11zon.webp https://thepharmadata.com/estrella-immunopharma-advances-starlight-1-trial/ 2025-02-22T10:51:23+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Estrella-Immunopharma-Advances-STARLIGHT-1-Trial.webp https://thepharmadata.com/wp-content/uploads/2025/02/Estrella-Immunopharma-Advances-STARLIGHT-1-Trial-to-Higher-Dose-Cohort-1024x684.webp https://thepharmadata.com/samsung-bioepis-launches-pyzchiva/ 2025-02-25T10:06:21+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Samsung-Bioepis-Launches-PYZCHIVA®.webp https://thepharmadata.com/wp-content/uploads/2025/02/Samsung-Bioepis-Launches-PYZCHIVA®-ustekinumab-ttwe-Biosimilar-to-Stelara-in-the-U.S.webp https://thepharmadata.com/revelation-biosciences-inc-secures-ongoing/ 2025-02-25T10:23:43+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Revelation-Biosciences-Inc.-Secures-Ongoing-NASDAQ-Listing-Approval-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/Revelation-Biosciences-Inc.-Secures-Ongoing-NASDAQ-Listing-Approval-1024x535.webp https://thepharmadata.com/fda-accepts-sbla-for-opdivo-yervoy/ 2025-02-25T10:37:58+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/FDA-Accepts-sBLA-for-Opdivo®-Yervoy®-in-MSI-HighdMMR.webp https://thepharmadata.com/wp-content/uploads/2025/02/FDA-Accepts-sBLA-for-Opdivo®-Yervoy®-in-MSI-HighdMMR-Cancers.webp https://thepharmadata.com/latus-bio-presents-preclinical-data-supporting/ 2025-02-25T10:54:25+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Latus-Bio-Presents-Preclinical-Data-Supporting-Its-Huntingtons-Disease-Gene-Therapy-Program-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/Latus-Bio-Presents-Preclinical-Data-Supporting-Its-Huntingtons-Disease-Gene-Therapy-Program.webp https://thepharmadata.com/an2-shares-strategic-update-on-phase-3/ 2025-02-25T11:02:07+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/AN2-Shares-Strategic-Update-on-Phase-3-EBO-301.webp https://thepharmadata.com/wp-content/uploads/2025/02/AN2-Shares-Strategic-Update-on-Phase-3-EBO-301-Trial-for-Treatment-Refractory-MAC-Lung-Disease.webp https://thepharmadata.com/synnovation-therapeutics-doses-first-patient-in/ 2025-02-25T11:13:14+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Synnovation-Therapeutics-Doses-First-Patient-in-Phase.webp https://thepharmadata.com/wp-content/uploads/2025/02/Synnovation-Therapeutics-Doses-First-Patient-in-Phase-I-Trial-for-PI3Kα-Inhibitor-SNV4818-1024x684.webp https://thepharmadata.com/halda-therapeutics-doses-first-patient-in-hld/ 2025-02-25T11:20:00+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Halda-Therapeutics-Doses-First-Patient-in-HLD-0915-Phase-12-Trial-for-mCRPC.webp https://thepharmadata.com/wp-content/uploads/2025/02/Halda-Therapeutics-Doses-First-Patient-in-HLD-0915-Phase-12.webp https://thepharmadata.com/bruker-expands-proteomics-capabilities-with-new/ 2025-02-25T11:31:41+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Bruker-Expands-Proteomics-Capabilities-with-New-Software-at-US-HUPO-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/Bruker-Expands-Proteomics-Capabilities-with-New-Software-at-US-HUPO-1024x536.webp https://thepharmadata.com/wp-content/uploads/2025/02/Bruker-Expands-Proteomics-Capabilities-with-New-Software_11zon-776x1024.webp https://thepharmadata.com/wp-content/uploads/2025/02/Bruker-Expands-Proteomics-Capabilities-with_11zon.webp https://thepharmadata.com/glaukos-receives-fda-acceptance-for-epioxa/ 2025-02-25T11:38:59+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Glaukos-Receives-FDA-Acceptance-for-Epioxa™-NDA-Submission-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/Glaukos-Receives-FDA-Acceptance-for-Epioxa™-NDA-Submission.webp https://thepharmadata.com/healx-begins-phase-2-trial-dosing-for-hlx-1502/ 2025-02-25T11:44:53+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Healx-Begins-Phase-2-Trial-Dosing-for-HLX-1502-in-Neurofibromatosis.webp https://thepharmadata.com/wp-content/uploads/2025/02/Healx-Begins-Phase-2-Trial-Dosing-for-HLX-1502-in-Neurofibromatosis-Type-1_11zon.webp https://thepharmadata.com/leo-pharmas-anzupgo-meets-phase-3-endpoint/ 2025-02-28T10:06:07+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/LEO-Pharmas-Anzupgo®-Meets-Phase-3-Endpoint-in-China-for-Chronic-Hand-Eczema-2.webp https://thepharmadata.com/wp-content/uploads/2025/02/LEO-Pharmas-Anzupgo®-Meets-Phase-3-Endpoint-in-China-for-Chronic-Hand-Eczema.webp https://thepharmadata.com/avitia-unveils-ai-powered-platform-for-fast/ 2025-02-28T10:18:47+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Avitia-Unveils-AI-Powered-Platform-for-Fast-Point-of-Care-Cancer-Testing.webp https://thepharmadata.com/wp-content/uploads/2025/02/Avitia-Unveils-AI-Powered-Platform-for-Fast-Point-of-Care-Cancer-Testing_11zon.webp https://thepharmadata.com/genethon-showcases-innovations-in-gene/ 2025-02-28T10:28:16+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Genethon-Showcases-Innovations-in-Gene-Therapy-on-Rare-Disease-Day.webp https://thepharmadata.com/wp-content/uploads/2025/02/Genethon-Showcases-Innovations-in-Gene-Therapy-on-Rare-Disease-Day_11zon-1.webp https://thepharmadata.com/aurinia-pharmaceuticals-announces-q4-2024/ 2025-02-28T11:29:37+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/pexels-rdne-7947634-1_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Aurinia-Pharmaceuticals-Announces-Q4-2024-Financial-Results-Updates-on-Corporate-Progress_11zon.webp https://thepharmadata.com/ipa-and-ribopro-partner-to-advance-mrna/ 2025-02-28T10:45:50+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/IPA-and-RIBOPRO-Partner-to-Advance-mRNA-Based-Antibody-Discovery-and-Expand-Immunotherapy-Frontiers.webp https://thepharmadata.com/wp-content/uploads/2025/02/IPA-and-RIBOPRO-Partner-to-Advance-mRNA-Based-Antibody-Discovery-and-Expand-Immunotherapy-Frontiers_11zon.webp https://thepharmadata.com/immune-onc-doses-first-patient-in-io-108-phase/ 2025-02-28T10:56:28+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Immune-Onc-Doses-First-Patient-in-IO-108-Phase-1b2-Liver-Cancer-Trial-with-Roche.webp https://thepharmadata.com/wp-content/uploads/2025/02/Immune-Onc-Doses-First-Patient-in-IO-108-Phase_11zon.webp https://thepharmadata.com/identiv-and-novanta-form-strategic-partnership/ 2025-02-28T11:04:35+05:30 https://thepharmadata.com/wp-content/uploads/2025/02/Identiv-and-Novanta-Form-Strategic-Partnership-to-Accelerate-RFID-Adoption-in-Healthcare-OEMs.webp https://thepharmadata.com/wp-content/uploads/2025/02/Identiv-and-Novanta-Form-Strategic-Partnership-to-Accelerate-RFID_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/02/Identiv-and-Novanta-Form-Strategic-Partnership-to-Accelerate-RFID-Adoption-in-Healthcare-OEMs_11zon.webp https://thepharmadata.com/sinovac-appoints-new-board-following/ 2025-03-01T09:55:17+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/SINOVAC-Appoints-New-Board-Following-Privy-Council-Ruling-2.webp https://thepharmadata.com/wp-content/uploads/2025/03/SINOVAC-Appoints-New-Board-Following-Privy-Council-Ruling-1024x684.webp https://thepharmadata.com/predictmedix-ai-unveils-advanced-ai/ 2025-03-01T10:04:35+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Predictmedix-AI-Unveils-Advanced-AI-Health-Stations-for-US-Market-Expansion-3.webp https://thepharmadata.com/wp-content/uploads/2025/03/Predictmedix-AI-Unveils-Advanced-AI-Health-Stations-for-US-Market-Expansion-2-1024x684.webp https://thepharmadata.com/vertex-gains-chmp-nod-for-kaftrio-label/ 2025-03-01T10:13:11+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Vertex-Gains-CHMP-Nod-for-KAFTRIO®-Label.webp https://thepharmadata.com/wp-content/uploads/2025/03/Vertex-Gains-CHMP-Nod-for-KAFTRIO®-Label-Expansion-in-Rare-CF-Mutations.webp https://thepharmadata.com/astria-begins-phase-3-alpha-orbit-trial/ 2025-03-01T10:24:38+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Astria-Begins-Phase-3-ALPHA-ORBIT-Trial-of-Navenibart-for-Hereditary-Angioedema.webp https://thepharmadata.com/wp-content/uploads/2025/03/Astria-Begins-Phase-3-ALPHA-_11zon.webp https://thepharmadata.com/bridgebio-oncology-and-helix-acquisition/ 2025-03-01T10:31:53+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/BridgeBio-Oncology-and-Helix-Acquisition-Announce.webp https://thepharmadata.com/wp-content/uploads/2025/03/BridgeBio-Oncology-and-Helix-Acquisition-Announce-Merger-to-Advance-RAS-PI3Kα-Therapies.webp https://thepharmadata.com/seismic-therapeutic-presents-preclinical-data/ 2025-03-01T10:39:51+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Seismic-Therapeutic-Presents-Preclinical-Data-on-S-8484.webp https://thepharmadata.com/wp-content/uploads/2025/03/Seismic-Therapeutic-Presents-Preclinical-Data-on-S-8484-for-Allergic-Diseases.png https://thepharmadata.com/chmp-recommends-eu-approval-of-enhertu/ 2025-03-01T10:54:39+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/CHMP-Recommends-EU-Approval-of-ENHERTU®-for-HER2-LowUltralow-Metastatic-Breast-Cancer.webp https://thepharmadata.com/wp-content/uploads/2025/03/CHMP-Recommends-EU-Approval-of-ENHERTU®-for-HER2-1024x684.webp https://thepharmadata.com/sarepta-therapeutics-opens-applications-for-8th/ 2025-03-01T11:01:28+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Sarepta-Therapeutics-Opens-Applications-for-8th-Annual-Route-79-Duchenne-Scholarship-Program.webp https://thepharmadata.com/wp-content/uploads/2025/03/Sarepta-Therapeutics-Opens-Applications-for-8th-Annual-Route_11zon.webp https://thepharmadata.com/arrowhead-pharmaceuticals-launches-fcs-patient/ 2025-03-01T11:13:22+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Arrowhead-Pharmaceuticals-Launches-FCS-Patient.webp https://thepharmadata.com/wp-content/uploads/2025/03/Arrowhead-Pharmaceuticals-Launches-FCS-Patient-Resources-on-Rare-Disease-Day_11zon.webp https://thepharmadata.com/incyte-to-present-latest-dermatology-portfolio/ 2025-03-01T11:19:00+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Incyte-to-Present-Latest-Dermatology-Portfolio-Data-at-2025-AAD-Annual-Meeting_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/03/Incyte-to-Present-Latest-Dermatology-Portfolio-at-2025-AAD-Annual-Meeting_11zon.webp https://thepharmadata.com/wedgewood-names-jessica-knopp-gwynne-chief/ 2025-03-01T11:29:46+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Wedgewood-Names-Jessica-Knopp-Gwynne-Chief-Revenue-Officer.webp https://thepharmadata.com/wp-content/uploads/2025/03/Wedgewood-Names-Jessica-Knopp-Gwynne-Chief-Revenue-Officer-to-Lead-Strategic-Growth.webp https://thepharmadata.com/demetra-holding-acquires-majority-stake-in/ 2025-03-01T11:37:27+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Demetra-Holding-Acquires-Majority-Stake-in-GetSet-Surgical-Expanding.webp https://thepharmadata.com/wp-content/uploads/2025/03/Demetra-Holding-Acquires-Majority-Stake-in-GetSet-Surgical-Expanding-Spine-Portfolio.webp https://thepharmadata.com/smithrx-adds-stelara-biosimilars-projecting/ 2025-03-01T11:53:31+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/SmithRx-Adds-Stelara-Biosimilars-Projecting.webp https://thepharmadata.com/wp-content/uploads/2025/03/SmithRx-Adds-Stelara-Biosimilars-Projecting-14.5M-Savings-1024x684.webp https://thepharmadata.com/qiagen-files-legal-action-to-protect-quantiferon/ 2025-03-03T15:51:01+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/QIAGEN-Files-Legal-Action-to-Protect-QuantiFERON.jpg https://thepharmadata.com/wp-content/uploads/2025/03/QIAGEN-Files-Legal-Action-to-Protect-QuantiFERON-IP-in-TB-Testing.png https://thepharmadata.com/celltrion-secures-ec-approval-for-avtozma/ 2025-03-04T09:33:32+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Celltrion-Secures-EC-Approval-for-Avtozma®-CT-P47-a-Biosimilar-to-RoActemra®.webp https://thepharmadata.com/wp-content/uploads/2025/03/Celltrion-Secures-EC-Approval-for_11zon-1024x535.webp https://thepharmadata.com/guardian-pharmacy-services-reports-q4-full/ 2025-03-04T09:45:47+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Guardian-Pharmacy-Services-Reports-Q4-Full-Year-2024-Results-2025-Outlook-Earnings-Call-Date.webp https://thepharmadata.com/wp-content/uploads/2025/03/Guardian-Pharmacy-Services-Reports-Q4-Full-Year-2024.webp https://thepharmadata.com/protagonist-and-takeda-report-positive-phase-3/ 2025-03-04T09:55:33+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Protagonist-and-Takeda-Report-Positive-Phase-3-VERIFY-Study-Results-for.webp https://thepharmadata.com/wp-content/uploads/2025/03/Protagonist-and-Takeda-Report-Positive-Phase-3-VERIFY-Study_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/03/Protagonist-and-Takeda-Report-Positive-Phase-3_11zon.webp https://thepharmadata.com/repare-therapeutics-shares-business-clinical/ 2025-03-04T10:05:19+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Repare-Therapeutics-Shares-Business-Clinical-Update-2024-Financial-Results.webp https://thepharmadata.com/wp-content/uploads/2025/03/Repare-Therapeutics-Shares-Business_11zon.webp https://thepharmadata.com/tenovi-and-geniemd-partner-to-expand-remote-care/ 2025-03-04T10:15:26+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Tenovi-and-GenieMD-Partner-to-Expand-Remote-Care-and-Improve-Medication-Adherence.webp https://thepharmadata.com/wp-content/uploads/2025/03/Tenovi-and-GenieMD-Partner-to-Expand-1024x684.webp https://thepharmadata.com/labvantage-launches-lims-8-9-to-boost-lab/ 2025-03-04T10:26:11+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/LabVantage-Launches-LIMS-8.9-to-Boost-Lab.webp https://thepharmadata.com/wp-content/uploads/2025/03/LabVantage-Launches-LIMS-8.9-to-Boost-Lab-Productivity-Efficiency.webp https://thepharmadata.com/surescripts-2024-report-highlights-surge-in/ 2025-03-04T10:32:39+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Surescripts-2024-Report-Highlights-Surge-in-Health-Intelligence-Sharing-Enhancing-Care-Quality-Access.webp https://thepharmadata.com/wp-content/uploads/2025/03/Surescripts-2024-Report-Highlights-Surge-in-Health-Intelligence_11zon.webp https://thepharmadata.com/revvitys-euroimmun-secures-ce-mark-for/ 2025-03-04T10:39:18+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Revvitys-EUROIMMUN-Secures-CE-Mark-for.webp https://thepharmadata.com/wp-content/uploads/2025/03/Revvitys-EUROIMMUN-Secures-CE-Mark-for-Innovative-Measles-Antibody-Test.webp https://thepharmadata.com/sotio-presents-promising-preclinical-data/ 2025-03-04T10:46:02+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/SOTIO-Presents-Promising-Preclinical-Data-on-SOT109-for-Colorectal-Cancer.webp https://thepharmadata.com/wp-content/uploads/2025/03/SOTIO-Presents-Promising-Preclinical-Data-on-SOT109-for-Colorectal-Cancer_11zon.webp https://thepharmadata.com/gensaic-partners-with-novo-nordisk-to-advance/ 2025-03-04T17:44:15+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Gensaic-Partners-with-Novo-Nordisk-to-Advance-Next-Gen-Precision-Therapies.jpg https://thepharmadata.com/wp-content/uploads/2025/03/Gensaic-Partners-with-Novo-Nordisk-to-Advance-Next-Gen-Precision-Therapies.png https://thepharmadata.com/osivax-secures-key-funding-to-advance-next-gen/ 2025-03-05T14:14:44+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Osivax.webp https://thepharmadata.com/wp-content/uploads/2025/03/Osivax-Secures-Key-Funding-to-Advance-Next-Gen-Influenza-Vaccines_11zon-1024x724.webp https://thepharmadata.com/fairjourney-biologics-acquires-charles-river/ 2025-03-05T14:22:04+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/FairJourney-Biologics-Acquires-Charles-Rivers-South.webp https://thepharmadata.com/wp-content/uploads/2025/03/FairJourney-Biologics-Acquires-Charles-Rivers-South-San-Francisco-Site.webp https://thepharmadata.com/centauri-therapeutics-advances-lead/ 2025-03-05T14:28:31+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Centauri-Therapeutics-Advances-Lead-Immunotherapy-for-Gram-Negative-Infections.webp https://thepharmadata.com/wp-content/uploads/2025/03/pexels-karolina-grabowska-4046948_11zon-1024x684.webp https://thepharmadata.com/fda-approves-tevimbra-for-esophageal-cancer/ 2025-03-05T14:38:27+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/TEVIMBRA-Gains-U.S.-Approval-for-First-Line-Esophageal-Cancer-Treatment-with-Chemotherapy.webp https://thepharmadata.com/wp-content/uploads/2025/03/TEVIMBRA-Gains-U.S.-Approval-for-First-Line-Esophageal-Cancer-Treatment-with-Chemotherapy_11zon.webp https://thepharmadata.com/amylyx-reports-q4-and-full-year-2024-financial/ 2025-03-05T14:47:18+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Amylyx-Reports-Q4-and-Full-Year-2024-Financial-Results.webp https://thepharmadata.com/wp-content/uploads/2025/03/Amylyx-Reports-Q4-and-Full-Year-2024-Financial-Results_11zon.webp https://thepharmadata.com/fda-grants-orphan-rare-pediatric-status-to/ 2025-03-05T14:56:26+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/FDA-Grants-Orphan-Rare-Pediatric-Status-to-NEU-001-for-Hirschsprung-Disease.webp https://thepharmadata.com/wp-content/uploads/2025/03/FDA-Grants-Orphan-Rare-Pediatric-Status-to-NEU-001-for-Hirschsprung-Disease_11zon.webp https://thepharmadata.com/nationsbenefits-emphasizes-nutrition-first/ 2025-03-05T15:03:11+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/NationsBenefits®-Emphasizes-Nutrition-First-GLP-1-Support-for-National-Nutrition-Month-2.webp https://thepharmadata.com/wp-content/uploads/2025/03/NationsBenefits®-Emphasizes-Nutrition-First-GLP-1-Support-for-National-Nutrition-Month.webp https://thepharmadata.com/medable-secures-cnil-approval-paving-the-way/ 2025-03-05T15:11:18+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Medable-Secures-CNIL-Approval-Paving-the-Way-for-Digital-Clinical-Trials-in-the-EU.webp https://thepharmadata.com/wp-content/uploads/2025/03/Medable-Secures-CNIL-Approval-Paving-the-Way-for-Digital-Clinical-Trials-in-the-EU_11zon.webp https://thepharmadata.com/shorla-oncology-expands-u-s-presence/ 2025-03-05T15:19:40+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Shorla-Oncology-Expands-U.S.-Presence-with-New-Sales-Market-Access-Teams-2.webp https://thepharmadata.com/wp-content/uploads/2025/03/Shorla-Oncology-Expands-U.S.-Presence-with-New-Sales-Market-Access-Teams_11zon.webp https://thepharmadata.com/wp-content/uploads/2025/03/Shorla-Oncology-Expands-U.S.-Presence-with-New-Sales-Market-Access-Teams.webp https://thepharmadata.com/repligen-acquires-908-devices-bioprocessing/ 2025-03-05T15:42:46+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Repligen-Acquires-908-Devices-Bioprocessing-Analytics-Portfolio-for-70-Million.webp https://thepharmadata.com/wp-content/uploads/2025/03/Repligen-Acquires-908-Devices-Bioprocessing-Analytics-Portfolio-for-70-Million_11zon.webp https://thepharmadata.com/parse-biosciences-progresses-towards-launching/ 2025-03-05T15:53:07+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Parse-Biosciences-Progresses-Towards-Launching-Single-.webp https://thepharmadata.com/wp-content/uploads/2025/03/Parse-Biosciences-Progresses-Towards-Launching-Single-Cell-Chromatin-Accessibility-Products.webp https://thepharmadata.com/epredia-secures-fda-510k-clearance-for/ 2025-03-05T16:00:14+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Epredia-Secures-FDA-510k-Clearance-for-E1000-Dx™-Digital-Pathology-Solution-2.webp https://thepharmadata.com/wp-content/uploads/2025/03/Epredia-Secures-FDA-510k-Clearance-for-E1000-Dx™-Digital-Pathology-Solution-1024x684.webp https://thepharmadata.com/cadrenal-therapeutics-partners-with-abbott-for/ 2025-03-05T16:08:33+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Cadrenal-Therapeutics-Partners-with-Abbott-for-Pivotal-Tecarfarin.webp https://thepharmadata.com/wp-content/uploads/2025/03/Cadrenal-Therapeutics-Partners-with-Abbott-for-Pivotal-Tecarfarin-Study-in-HeartMate-3™-LVAD-Patients.webp https://thepharmadata.com/genedx-expands-exome-and-genome-testing/ 2025-03-05T16:18:52+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/GeneDx-Expands-Exome-and-Genome-Testing-Access-Adding-Cerebral-Palsy-as-a-New-Indication.webp https://thepharmadata.com/wp-content/uploads/2025/03/GeneDx-Expands-Exome-and-Genome-Testing-Access-Adding-Cerebral-Palsy-as-a-New-Indication_11zon.webp https://thepharmadata.com/bionova-launches-new-process-development/ 2025-03-05T16:49:49+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Bionova-Launches-New-Process-Development-and-Pilot-Plant-in-Fremont-1.webp https://thepharmadata.com/wp-content/uploads/2025/03/Bionova-Launches-New-Process-Development-and-Pilot-Plant-in-Fremont_11zon.webp https://thepharmadata.com/fda-accepts-sbla-for-genentechs-gazyva/ 2025-03-06T14:19:06+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/FDA-Accepts-sBLA-for-Genentechs-Gazyva-in.webp https://thepharmadata.com/wp-content/uploads/2025/03/FDA-Accepts-sBLA-for-Genentechs-Gazyva-in-Lupus-Nephritis.webp https://thepharmadata.com/orbis-medicines-appoints-industry-veteran/ 2025-03-06T14:37:29+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Orbis-Medicines-Appoints-Industry-Veteran-Mikael-Dolsten-as-Board-Chair.webp https://thepharmadata.com/wp-content/uploads/2025/03/Orbis-Medicines-Appoints-Industry-Veteran-Mikael-Dolsten-as-Board-Chair_11zon.webp https://thepharmadata.com/leo-pharma-survey-chronic-hand-eczema/ 2025-03-06T15:41:14+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/LEO-Pharma-Survey-Chronic-Hand-Eczema-Misunderstood-and-Undermanaged.webp https://thepharmadata.com/wp-content/uploads/2025/03/LEO-Pharma-Survey-Chronic-Hand-Eczema-Misunderstood.webp https://thepharmadata.com/bicycle-therapeutics-announces-inducement-grants/ 2025-03-06T15:56:33+05:30 https://thepharmadata.com/wp-content/uploads/2025/03/Bicycle-Therapeutics-Announces-Inducement-Grants.webp https://thepharmadata.com/wp-content/uploads/2025/03/Bicycle-Therapeutics-Announces-Inducement-Grants_11zon.webp